Cargando…

Olaparib-Induced Immune-Mediated Liver Injury

Immune-mediated drug-induced liver injury can be triggered by multiple classes of medications including immunotherapies. Olaparib is a first-in-class oral inhibitor of poly (adenosine diphosphate-ribose) polymerase (an enzyme involved in DNA replication and repair) that is approved as maintenance tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alshelleh, Mohammad, Park, Jennifer, John, Veena, Rishi, Arvind, Bernstein, David, Roth, Nitzan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751767/ https://www.ncbi.nlm.nih.gov/pubmed/35028326 http://dx.doi.org/10.14309/crj.0000000000000735

Ejemplares similares

Olaparib-induced pseudoporphyria in a patient with ovarian cancer
por: Clark, Abigale, et al.
Publicado: (2023)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Metronidazole Induced Liver Injury: A Rare Immune Mediated Drug Reaction
por: Kancherla, Dayakar, et al.
Publicado: (2013)

Immune-mediated Drug-induced Liver Injury Caused by Laninamivir Octanoate Hydrate
por: Kawaguchi, Toshihiro, et al.
Publicado: (2019)

A rare case of Polyarteritis Nodosa associated with autoimmune hepatitis: a case report
por: Kennedy, Freda, et al.
Publicado: (2021)

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
por: Mahdi, Haider, et al.
Publicado: (2021)

Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
por: Sekine, Mana, et al.
Publicado: (2023)

Presentation, patterns and predictive value of baseline liver tests on outcomes in COVID-19 patients without chronic liver disease
por: Bernstein, David, et al.
Publicado: (2021)

Immune‐mediated drug‐induced liver injury secondary to Omeprazole: A case report
por: Seife Hassen, Sara, et al.
Publicado: (2020)

BRCA1 Reversion Mutation Confers Resistance to Olaparib and Camrelizumab in a Patient with Breast Cancer Liver Metastasis
por: Pan, Jia-Ni, et al.
Publicado: (2021)

Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
por: Bangham, Madeleine, et al.
Publicado: (2016)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Olaparib: Transcending mutational barriers
por: Chandna, Abhishek
Publicado: (2019)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Risk factors and outcomes for acute-on-chronic liver failure in COVID-19: a large multi-center observational cohort study
por: Satapathy, Sanjaya K., et al.
Publicado: (2021)

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein
por: Ghiringhelli, Francois, et al.
Publicado: (2016)

Successful olaparib desensitization using a novel one-day protocol
por: Zhu, Rongbo, et al.
Publicado: (2020)

Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy
por: Himeji, Daisuke, et al.
Publicado: (2021)

BRCA2 reversion mutation confers resistance to olaparib in breast cancer
por: Yamamoto, Shinya, et al.
Publicado: (2023)

POS-863 Acute Kidney Injury in COVID 19 patients admitted to tertiary hospital
por: Oweis MD, A., et al.
Publicado: (2022)

The combination of olaparib and camptothecin for effective radiosensitization
por: Miura, Katsutoshi, et al.
Publicado: (2012)

Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin
por: Vareki, Saman Maleki, et al.
Publicado: (2014)

Expression of MUS81 Mediates the Sensitivity of Castration-Resistant Prostate Cancer to Olaparib
por: Gong, Lifeng, et al.
Publicado: (2022)

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report
por: Xie, Yuan, et al.
Publicado: (2016)

Olaparib Monotherapy for BRIP1-Mutated High-Grade Serous Endometrial Cancer
por: Nakamura, Kohei, et al.
Publicado: (2020)

Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib
por: Gross, Maya, et al.
Publicado: (2022)

Incidence and outcomes of acute kidney injury in octogenarians in Jordan
por: Oweis, Ashraf O., et al.
Publicado: (2018)

Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers
por: Freire Boullosa, Laurie, et al.
Publicado: (2023)

Liver transplantation for azithromycin-induced severe liver injury
por: Park, Hyun Joon, et al.
Publicado: (2020)

Immune-mediated Liver Injury in Hepatitis B Virus Infection
por: Oh, In Soo, et al.
Publicado: (2015)

Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models
por: Gerussi, Alessio, et al.
Publicado: (2021)

Recent Advances in Models of Immune-Mediated Drug-Induced Liver Injury
por: Tasnim, Farah, et al.
Publicado: (2021)

Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
por: Cecchini, Michael, et al.
Publicado: (2023)

Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses
por: Moran, Jennifer, et al.
Publicado: (2023)

Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant
por: Kuemmel, Sherko, et al.
Publicado: (2020)

Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy
por: Kumeta, Toko, et al.
Publicado: (2019)

Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation
por: Li, Xiaofen, et al.
Publicado: (2021)

Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2022)

Profile of olaparib in the treatment of advanced ovarian cancer
por: Chase, Dana M, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_f27cjg3m40m89ti77fm1k9sma1